None listed
Conditions
Interventions
Drug : 1) Individuals meeting the inclusion criteria are screened and all participants provided written informed consent before participation.
Patients at the first visit were identified with clini
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients over 19 years of age 2. Typical asthma symptoms (night/dawn, cold, exercise, changes in weather, smoke/allergens/stimulating odor exposure, and difficulty breathing, coughing, chest tightness) 3.Positive bronchodilator response (FEV1 is 12%, 200ml increase) or metacholine provocation test (PC20 less than 16mg/mL) 4. Patients who entered GINA Step 3 with a low dose ICS/LABA treatment 5. Patients who can use dry powder inhaler
Exclusion criteria
Exclusion criteria: 1. Malignancy and other serious diseases that may affect this study 2. Previous use of Foster Nexthaler and Duoresp Spiromax inhaler. 3. Pregnancy or lactation 4. Not suitable for use of dry powder inhaler 5. refusal to participate the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced expiratory flow at 25 and 75% of the pulmonary volume (FEF25-75%) | — |
Secondary
| Measure | Time frame |
|---|---|
| Pre-bronchodilator FEV1;Pre-bronchodilator FEV1/FVC;Asthma Control Test (ACT) ;Asthma Control Questionnaire (ACQ);Quality of Life Questionnaire for Adult Korean Asthmatics (QLQAKA);Safety ;Inhaler preference | — |
Countries
Korea, Republic of
Contacts
Public ContactSung-Yoon Kang
Gachon University Gil Medical Center
Outcome results
None listed